Browse the evidence

Advancements in laparoscopic surgical technique have improved the safety and efficacy of bariatric metabolic surgery.

Surgeons should adopt new laparoscopic techniques to enhance patient outcomes in bariatric surgery.

Recent insights into pathophysiological mechanisms suggest that OSA may be divided into distinct subgroups.

Understanding the subgroups in OSA may lead to more targeted treatments.

Recent drug candidates show a convincing reduction of sleep disordered breathing in both short and intermediate term.

New drug candidates may offer effective treatment options for OSA patients.

The time of day does not significantly moderate the association between MVPA and all-cause mortality.

Patients can perform MVPA at any time of day without concern for timing affecting mortality.

Substituting evening MVPA with morning MVPA does not lead to appreciable changes in all-cause mortality.

The timing of MVPA (morning vs evening) is not critical for mortality outcomes.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

If clinicians elect to use compounded incretin‐based therapy, they must consider the potential harms and benefits for each patient.

Clinicians should evaluate individual patient needs and educate them on therapy administration.

Obesity is associated with comorbidities such as metabolic and cardiovascular diseases, orthopaedic and psychiatric conditions, and cancer.

Healthcare providers should be aware of the serious health risks associated with obesity.

Diet and exercise are not effective as sole management of severe obesity.

Clinicians should consider additional interventions beyond diet and exercise for severe obesity.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Redemption was higher for females, Asian participants, and those reporting Spanish as their preferred language compared to their counterparts.

Demographic factors such as gender, ethnicity, and language preference may influence redemption rates in produce prescription programs.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.

No significant further benefits of ingesting multi-ingredient supplements (MTN) compared to calorie equivalent comparator (COMP) supplements were identified for fat-free mass (FFM), upper-body strength, lower-body strength, and functional capacity.

Practitioners should consider that multi-ingredient supplements may not provide additional benefits over calorie equivalent supplements for body composition and performance in this population.

Obesity is a debilitating disease that requires refined, concept-driven therapeutic approaches.

Health professionals should adopt refined therapeutic approaches to address obesity.

The 'Behavioral Balance Model' integrates biological, psychological, social, economic, and environmental aspects of obesity.

Practitioners should consider a multifaceted approach to understanding and treating obesity.

Further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.

Practitioners should be aware that while glucagon and GLP-1 co-agonists show promise, more research is needed before widespread clinical application.

Cagrilintide, a stable amylin analogue, is under clinical development for obesity treatment.

Cagrilintide may offer a new approach to obesity management.

Nonshivering thermogenesis (NST) has potential for activating energy balance processes without significant side effects.

Practitioners may consider NST as a viable strategy for enhancing energy balance in obesity management.

There was no significant relative change in disability benefit receipt for the ILI group compared to controls.

Intensive lifestyle interventions may not affect disability benefit receipt despite improving employment.

Whey protein supplementation did not differentially influence performance, cardiorespiratory fitness, upper and lower body strength, immune or hormonal adaptations following 6 weeks of concurrent training.

Practitioners should note that whey protein supplementation may not provide additional benefits during concurrent training.

The 7-year cardiovascular risk was 17.4% in the surgery group with preoperative preparation and 18.8% in the no-surgery group, with a risk difference of -1.4.

Preoperative preparation combined with bariatric surgery does not significantly reduce cardiovascular risk.